The company's low P/S ratio may indicate anticipated continu...
The company's low P/S ratio may indicate anticipated continued revenue decline. Its revenue trend lags behind the industry's expected 35% growth in the next year. This low P/S ratio and shrinking revenues could disappoint shareholders in the future.
ShanXi C&Y Pharmaceutical Group Co., Ltd. (SZSE:300254) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment